Sydney, May 18, 2026, 00:03 (AEST)
CSL Ltd starts Monday as traders weigh last week’s 18% fall. The drop followed a profit warning and a non-cash impairment of about $5 billion, a write-down that reduces asset values but has no instant cash impact. The ASX cash market is still shut after the weekend, with trading set to start around 09:59:45 Sydney time.
CSL’s slide is weighing on the market now, where it used to be a safe spot. CSL ended Friday at A$97.96, up 0.72% for the day, but down 18.3% across five sessions. The S&P/ASX 200 closed at 8,630.8, dropping 0.11% on Friday.
CSL trimmed its fiscal 2026 revenue forecast to roughly $15.2 billion and now sees NPATA at about $3.1 billion, both set on a constant-currency basis. The move followed interim CEO Gordon Naylor’s 90-day review.
Naylor said CSL’s “growth initiatives are working” but financial benefits will take more time to appear. He said he is confident the company can return to profitable growth. But after the latest downgrade, that line may need more than words.
CSL said revenue is under pressure from three areas: around $300 million tied to U.S. immunoglobulin and other plasma medicines, about $200 million from a weaker albumin market in China, and roughly $150 million from the Middle East conflict, slower HEMGENIX growth, and iron drug rivals. The company also flagged lower revenue from channel inventory normalisation, with distributors needing to sell off existing stock.
CSL shares plunged after the news. Reuters said CSL dropped as much as 17.8% on Monday to A$98.59, a level last seen in January 2017, and settled down 16% at the close. By the end of the week, the stock finished at A$97.96.
Mark Gardner, founder and CEO of MPC Markets, said the “back-to-back downgrades” at CSL threw its transparency into question. Gardner flagged the lack of a permanent CEO and said the company was still coping with the impact of what he called an overpriced buy and some real revenue pressures. Sahm
CSL, Grifols and Takeda make up a tight three-player field in plasma therapies, according to Morningstar. That means investors stay fixed on costs of collection, pricing and CSL’s ability to hold margins as demand rises.
CSL Seqirus last week said it signed a multi-year deal with the Pan American Health Organization to secure millions of pandemic flu vaccine doses for Latin America and the Caribbean. “A pandemic doesn’t wait for us to be ready,” said Gonzalo Pereira, CSL Seqirus’ Latin America general manager. Global Newsroom | CSL
But investors might see the impairment as more than just an accounting hit. If U.S. immunoglobulin inventory moves slow, China albumin prices stay low, iron rivals push harder, or the CEO seat stays empty, any bounce in the stock could be short-lived. CSL said it’s still working on the write-down, with more analysis, an audit, and board approval to come.
Citi is less bullish on CSL, moving the stock to Neutral from Buy and slashing its price target to A$110 from A$200. The bank said some negative news is likely in the shares now, but flagged that immunoglobulin and albumin are still not “on a firm footing.” TipRanks
Trust is front and center for the week ahead, with little on the company news calendar. CSL told markets not to expect a detailed financial or operational update until its full-year results drop Aug. 18. So for now, all eyes are on Monday’s open, what brokers do with their numbers, and any leadership signals to guide sentiment.
